Università degli Studi di Brescia

Quick facts

Marketed products

• Dinoprostone vaginal pessary · Obstetrics
  Dinoprostone is a prostaglandin F2α analog that binds to prostaglandin receptors on the uterus to stimulate myometrial contractions and promote cervical ripening and labor induction.
• formoterol - beclometasone
• Ketorolac + Ranibizumab · Ophthalmology
  Ketorolac reduces ocular inflammation via COX inhibition while ranibizumab blocks VEGF-A to inhibit pathological neovascularization in the eye.
• mixture of amino and keto acids
• Nepafenac 0.1% eyedrops
• Omega-3 Supplementation · Cardiovascular
  Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways by competing with arachidonic acid metabolism and inhibiting pro-inflammatory eicosanoid production.
• Pranoprofen Eyedrops · Ophthalmology
  Pranoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation in the eye.
• Salmeterol Fluticasone · Respiratory/Pulmonology
  Salmeterol/fluticasone is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.

Phase 3 pipeline

• Bromfenac 0.09% eyedrops · Ophthalmology
  Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
• Indomethacin 0.5% eyedrops · Ophthalmology
  Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
• Ketorolac 0.5% eyedrops · Ophthalmology
  Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain in the eye.
• n-3 PUFAs · Cardiovascular
  n-3 PUFAs are a class of fatty acids that exert anti-inflammatory effects and improve cardiovascular health.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Università degli Studi di Brescia portfolio CI brief
• Università degli Studi di Brescia pipeline updates RSS